Geron to Webcast Analyst and Investor Meeting on Company's Oncology Programs on
March 29, 2011
MENLO PARK, Calif., Mar 24, 2011 (BUSINESS WIRE) -- Geron Corporation (GERN)
today announced that it will host a live webcast of the analyst and investor
meeting on its oncology programs being held in New York from 12:15 p.m. to 1:30
p.m. EDT on Tuesday, March 29, 2011.
Members of Geron's oncology team and management, including Stephen M. Kelsey,
M.D., FRCP, FRCPath, Executive Vice President and Chief Medical Officer and Monic
Stuart, M.D., Executive Medical Director, will present the progress of the
company's anti-cancer therapies in Phase 2 clinical development. The presentation
will focus on the company's telomerase inhibitor drug (imetelstat sodium -
GRN163L) and the recently in-licensed peptide-conjugated paclitaxel derivative
designed to penetrate the blood-brain barrier (GRN1005).
The webcast for the live audio and slide presentation will be available at
phx.corporate-ir.net.
The presentation will be archived for replay and available at the same address
one hour after conclusion of the live event for a period of 30 days. It is
recommended that listeners log on 15 minutes early in order to register and
download any necessary software.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer
and chronic degenerative diseases. The company is advancing anti-cancer therapies
through multiple Phase 2 clinical trials in different cancers by targeting the
enzyme telomerase and with a compound designed to penetrate the blood-brain
barrier. The company is developing cell therapy products from differentiated
human embryonic stem cells for multiple indications, including central nervous
system (CNS) disorders, heart failure, diabetes and osteoarthritis, and has
initiated a Phase 1 clinical trial in spinal cord injury. For more information
about Geron, visit geron.com.
SOURCE: Geron Corporation
Geron Corporation
Anna Krassowska, Ph.D., 650-473-7765
Investor and Media Relations
info@geron.com |
